Le Lézard
Classified in: Health
Subject: SVY

Global Diarrhea and Constipation Drug Development Pipeline Review 2018: 79 Products in Development


DUBLIN, Aug. 17, 2018 /PRNewswire/ --

The "Diarrhea and Constipation Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Diarrhea and Constipation Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.

There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.

There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.

Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.

Scope

Key Topics Covered:

1 Tables & Figures

2 Introduction
2.1 Diarrhea and Constipation Report Coverage
2.2 Constipation - Overview
2.3 Diarrhea - Overview

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/trzlv8/global_diarrhea?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 16:40
Pfizer Declares Second-Quarter 2024 Dividend
Pfizer Inc. today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company's common stock, payable June 14, 2024, to holders of the Common Stock of record at the close of business on May 10, 2024. The...

at 16:35
Ecolab to Webcast Annual Meeting on May 2, 2024
Ecolab will host a live webcast of its annual meeting of stockholders. As indicated in our proxy statement, the 2024 Annual Meeting of Stockholders will be a virtual-only meeting. Details for the public webcast are as follows: TIME:...

at 16:35
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Summit Therapeutics Inc. ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens....

at 16:35
Hapbee Announces Closing of Private Placement
Hapbee Technologies, Inc. ("Hapbee" or the "Company"), the digital wellness technology company is pleased to confirm that it has completed a non-brokered private placement of units of the Company ("Units") for aggregate gross proceeds to the...

at 16:30
Ansys and TSMC Enable a Multiphysics Platform for Optics and Photonics, Addressing Needs of AI, HPC Silicon Systems
Collaboration on TSMC's COUPE silicon photonics platform dramatically speeds chip-to-chip and machine-to-machine communication for cloud, datacenters, HPC, and AI chips / Key Highlights Ansys and TSMC deliver a high-fidelity multiphysics solution to...

at 16:30
The Cigna Group Declares Quarterly Dividend
The Board of Directors of The Cigna Group today declared a cash dividend of $1.40 per share of its common stock, payable on June 20, 2024 to shareholders of record as of the close of business on June 4, 2024....

More news about Health...


News published on and distributed by: